序号 |
論文（專著） 名稱/刊名/作者 |
年卷頁碼（xx年xx卷xx頁） |
發表（出版）時間（年月日） |
他引總次數 |
檢索數據庫 |
1 |
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. Journal of thoracic oncology.Zhang, Y., Zeng, L., Zhou, C., Li, Y., Wu, L., Xia, C., Jiang, W., Hu, Y., Liao, D., Xiao, L., Liu, L., Yang, H., Xiong, Y., Guan, R., Lizaso, A., Mansfield, A. S., & Yang, N. (2020).共同第一作者排第一(1/5), PMID: 32112982 |
Journal of thoracic oncology: 15(6), 1027–1036. |
2020 Jun. Journal Impact Factor (2021): 20.121 |
35 |
Web of Science |
2 |
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial. JAMA network open. Zhang, X., Xiong, Y., Xia, Q., Wu, F., Liu, L., Zhou, Y., Zeng, L., Zhou, C., Xia, C., Jiang, W., Liao, D., Xiao, L., Liu, L., Yang, H., Guan, R., Li, K., Wang, J., Lei, G.,Zhang, Y., & Yang, N. (2020).通訊作者(1/1), PMID: 32191330 |
JAMA network open, 3(3), e201226. |
2020 Dec. Journal Impact Factor (2021): 13.353 |
12 |
Web of Science |
3 |
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. European journal of cancer. Peng, X., Long, X., Liu, L., Zeng, L., Yang, H., Jiang, W., Liao, D., Li, K., Wang, J., Lizaso, A., Mao, X., Xu, Q., Mansfield, A. S., Yang, N., &Zhang, Y. (2020).通訊作者(1/2), PMID: 33171317 |
European journal of cancer (Oxford, England : 1990), 141, 199–208. |
2019 Apr. Journal Impact Factor (2021): 10.022 |
8 |
Web of Science |
4 |
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. Journal of the National Cancer Institute, Jing, Y.,Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., Lou, Y., Lin, S. H., Diao, L., Liu, H., Chen, X., Mills, G. B., & Han, L. (2021).共同第一作者排第二(2/4), PMID: 33705549 |
Journal of the National Cancer Institute, 113(10), 1396–1404. |
2021 Oct 1. Journal Impact Factor (2021): 11.816 |
9 |
Web of Science |
5 |
Profiling of immune features to predict immunotherapy efficacy. Innovation (New York, N.Y.). Ye, Y.,Zhang, Y., Yang, N., Gao, Q., Ding, X., Kuang, X., Bao, R., Zhang, Z., Sun, C., Zhou, B., Wang, L., Hu, Q., Lin, C., Gao, J., Lou, Y., Lin, S. H., Diao, L., Liu, H., Chen, X., Mills, G. B., … Han, L. (2021).共同第一作者排第二(2/4), PMID: 34977836 |
Innovation (New York, N.Y.), 3(1), 100194. |
2021 Dec 2, Journal Impact Factor (2021): 28.506 |
7 |
Web of Science |
6 |
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.Zhang, Y., Huang, Z., Zeng, L., Zhang, X., Li, Y., Xu, Q., Yang, H., Lizaso, A., Xu, C., Liu, J., Wang, W., Song, Z., Ou, S. I., & Yang, N. (2022).共同第一作者排第1(1/3), 共同通訊排第二（2/2）, PMID: 35361870 |
NPJ precision oncology, 6(1), 20. |
2022 Mar 31, Journal Impact Factor (2021): 10.092 |
3 |
Web of Science |
7 |
Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. Zhang, Y., Zhang, X., Zhang, R., Xu, Q., Yang, H., Lizaso, A., Xu, C., Liu, J., Wang, W., Ou, S. I., Zhang, J., Song, Z., & Yang, N. (2021). 共同第一作者排第1(1/3), 共同通訊排第二（2/2）, PMID: 34663309 |
BMC medicine, 19(1):245 |
2021 Oct 19, Journal Impact Factor (2021): 11.150 |
5 |
Web of Science |
8 |
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.Zhang, Y., Zhang, X., Zhang, R., Xu, Q., Yang, H., Lizaso, A., Xu, C., Liu, J., Wang, W., Ou, S. I., Zhang, J., Song, Z., & Yang, N. (2021).共同第一作者排第1(1/3), 共同通訊排第二（2/2）, PMID: 34511132 |
BMC medicine, 19(1), 206. |
2021 Sep 13, Journal Impact Factor (2021): 11.150 |
5 |
Web of Science |
